| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2375MU2009 | 2009-10-12 | ||
| PCT/IN2010/000677WO2011051966A2 (en) | 2009-10-12 | 2010-10-12 | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| Publication Number | Publication Date |
|---|---|
| EP2488180A2 EP2488180A2 (en) | 2012-08-22 |
| EP2488180A4true EP2488180A4 (en) | 2013-03-27 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10826234AWithdrawnEP2488180A4 (en) | 2009-10-12 | 2010-10-12 | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| Country | Link |
|---|---|
| US (1) | US20120202849A1 (en) |
| EP (1) | EP2488180A4 (en) |
| WO (1) | WO2011051966A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009230718B2 (en) | 2008-03-26 | 2013-07-11 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US20120177730A1 (en) | 2011-01-07 | 2012-07-12 | Elcelyx Therapeutics, Inc. | Chemosensory Receptor Ligand-Based Therapies |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| CN103648498A (en)* | 2011-07-12 | 2014-03-19 | Ipca实验室有限公司 | Pharmaceutical combination |
| JP2015503582A (en) | 2012-01-06 | 2015-02-02 | エルセリクス セラピューティクス インコーポレイテッド | Biguanide compositions and methods of treating metabolic disorders |
| NZ626578A (en) | 2012-01-06 | 2016-11-25 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| AR091739A1 (en)* | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK |
| US20140066469A1 (en)* | 2012-08-21 | 2014-03-06 | Department Of Veterans Affairs | Treatment of diseases associated with inflammation |
| EP4215205A1 (en) | 2013-01-03 | 2023-07-26 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| CN108434138A (en)* | 2013-03-15 | 2018-08-24 | 小利兰·斯坦福大学托管委员会 | For treating ethyl hydroxychloroquine is gone with inflammation relevant disease |
| US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| WO2016162886A1 (en)* | 2015-04-07 | 2016-10-13 | Ipca Laboratories Limited | Hcqs for prophylaxis and treatment of statin induced diabetes |
| CN107922404B (en)* | 2015-06-30 | 2021-06-29 | 艾格集团国际公司 | Use of chloroquine and clemizole compounds for the treatment of inflammation and cancer |
| RU2018120599A (en) | 2015-11-06 | 2019-12-09 | Джемфир Терапьютикс, Инк. | TREATMENT OF MIXED DYSLIPIDEMIA |
| EP3241552A1 (en)* | 2016-05-02 | 2017-11-08 | Jansfat Biotechnology Co., Ltd. | Compositions and methods for lipid metabolism disorder |
| US20230263797A1 (en)* | 2021-08-26 | 2023-08-24 | Unm Rainforest Innovations | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States |
| CN115282131B (en)* | 2022-07-26 | 2023-10-10 | 东莞广州中医药大学研究院 | Pharmaceutical composition for treating non-alcoholic fatty liver and application thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8440695B2 (en)* | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
| US20080194575A1 (en)* | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
| US20090087483A1 (en)* | 2007-09-27 | 2009-04-02 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
| Title |
|---|
| DELGADO ET AL: "Evolving trends in nonalcoholic fatty liver disease", EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 2, 4 February 2008 (2008-02-04), pages 75 - 82, XP022452332, ISSN: 0953-6205, DOI: 10.1016/J.EJIM.2007.02.034* |
| UTZSCHNEIDER K M ET AL: "Review: The role of insulin resistance in nonalcoholic fatty liver disease", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 200612 US, vol. 91, no. 12, December 2006 (2006-12-01), pages 4753 - 4761, ISSN: 0021-972X* |
| YOUNOSSI Z M: "Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 28, no. 1, 1 July 2008 (2008-07-01), pages 2 - 12, XP002661670, ISSN: 0269-2813, [retrieved on 20080411], DOI: 10.1111/J.1365-2036.2008.03710.X* |
| Publication number | Publication date |
|---|---|
| WO2011051966A2 (en) | 2011-05-05 |
| US20120202849A1 (en) | 2012-08-09 |
| EP2488180A2 (en) | 2012-08-22 |
| WO2011051966A3 (en) | 2011-07-07 |
| Publication | Publication Date | Title |
|---|---|---|
| EP2488180A4 (en) | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease | |
| IL231512A0 (en) | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease | |
| IL234133B (en) | Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease | |
| IL228988A (en) | Antibody compositions for the treatment of immune related diseases | |
| EP2549997A4 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| PL2419114T3 (en) | Bacterial compositions for prophylaxis and treatment of degenerative disease | |
| EP2498602A4 (en) | Stabilized formulations of fatty acids | |
| IL216399A0 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| PT2429507T (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
| IL220076A0 (en) | Biologically active food additive for the prophylaxis of osteoporosis diseases | |
| IL209360A (en) | Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma | |
| EP2236137A4 (en) | Pharmaceutical composition for treatment of fatty liver diseases | |
| IL213354A (en) | Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines | |
| ZA201009072B (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
| PL2391353T3 (en) | Pharmaceutical compositions of trimetazidine | |
| HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
| ZA201200659B (en) | Pharmaceutical composition of isoniazid | |
| IL200753A (en) | Pharmaceutical composition comprising ib-meca for the treatment of psoriasis | |
| EP2413696A4 (en) | Compositions for treatment of alzheimer's disease | |
| GB0902648D0 (en) | Pharmaceutical compounds and compositions | |
| EP2480099A4 (en) | Compositions and methods for the prevention and treatment of metabolic diseases | |
| HU0900364D0 (en) | Preventive composition for treatment of disease of honey-bees caused by cck | |
| IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| AU2009905926A0 (en) | Methods and compositions for the treatment of osteoarticular disease |
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase | Free format text:ORIGINAL CODE: 0009012 | |
| 17P | Request for examination filed | Effective date:20120405 | |
| AK | Designated contracting states | Kind code of ref document:A2 Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR | |
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched | Effective date:20130225 | |
| RIC1 | Information provided on ipc code assigned before grant | Ipc:A61P 1/16 20060101ALI20130219BHEP Ipc:A61K 31/155 20060101ALI20130219BHEP Ipc:A61K 31/40 20060101ALI20130219BHEP Ipc:A61K 31/4706 20060101AFI20130219BHEP | |
| 17Q | First examination report despatched | Effective date:20131219 | |
| STAA | Information on the status of an ep patent application or granted ep patent | Free format text:STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN | |
| 18D | Application deemed to be withdrawn | Effective date:20160503 |